Abbisko Cayman (2256) Fundamentals 2026 — P/E 113.8x, Revenue Analysis | SniperIQ

0.54 on the HKSE. This SniperIQ fundamentals page covers Abbisko Cayman's valuation (P/E 113.8x, P/B 3.0x), profitability (net margin 9.0%), revenue (¥596M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Abbisko Cayman's market cap?

Abbisko Cayman (2256) has a market capitalization of approximately HK$7.6B, trading at HK

0.54 on the HKSE. Market cap moves with the live share price.

What is Abbisko Cayman's P/E ratio?

Abbisko Cayman's trailing twelve-month P/E ratio is 113.8x, with a price-to-book (P/B) of 3.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Abbisko Cayman?

Abbisko Cayman runs a net profit margin of 9.0%, a gross margin of 100.0%, and an operating margin of 4.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Abbisko Cayman generate?

Abbisko Cayman reported revenue of ¥596M for fiscal year 2025, with net income of ¥54M and earnings per share (EPS) of 0.0861. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Abbisko Cayman pay a dividend?

Abbisko Cayman does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Abbisko Cayman financially healthy?

Abbisko Cayman carries a debt-to-equity ratio of 0.16x and a current ratio of 4.98x, with a market beta of 1.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Abbisko Cayman a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Abbisko Cayman (2256) the key facts are: market cap HK$7.6B, P/E 113.8x, revenue ¥596M, 52-week range 8.34-19.78. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.